Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Enfortumab Vedotin-ejfv in Muscle Invasive Bladder Urothelial Carcinoma: NCT06809140 Clinical Landscape Report 2026
16 October 2026
NCT06809140 clinical landscape for Muscle Invasive Bladder Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
BBT-001(Bambusa Therapeutics) in Dermatitis, Atopic: NCT06808477 Clinical Landscape Report 2026
16 October 2026
NCT06808477 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vedolizumab in Acute Myeloid Leukemia: NCT06815003 Clinical Landscape Report 2026
16 October 2026
NCT06815003 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Succimer in Acute Myeloid Leukemia: NCT06811233 Clinical Landscape Report 2026
16 October 2026
NCT06811233 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Metformin Hydrochloride in Multiple Sclerosis, Relapsing-Remitting: NCT06812585 Clinical Landscape Report 2026
16 October 2026
NCT06812585 clinical landscape for Multiple Sclerosis, Relapsing-Remitting: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
KK-2845 in Relapsing acute myeloid leukemia: NCT06812104 Clinical Landscape Report 2026
16 October 2026
NCT06812104 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Eciskafusp alfa(Roche) in Non-Muscle Invasive Bladder Neoplasms: NCT06816017 Clinical Landscape Report 2026
16 October 2026
NCT06816017 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Avelumab in Advanced Urothelial Carcinoma: NCT06820255 Clinical Landscape Report 2026
16 October 2026
NCT06820255 clinical landscape for Advanced Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Quizartinib Hydrochloride in Acute Myeloid Leukemia with FLT3/ITD Mutation: NCT06824168 Clinical Landscape Report 2026
16 October 2026
NCT06824168 clinical landscape for Acute Myeloid Leukemia with FLT3/ITD Mutation: endpoints, sponsor, phase, geography, readouts, asset context and developme…
9 min read
Selinexor in Relapse multiple myeloma: NCT06822972 Clinical Landscape Report 2026
16 October 2026
NCT06822972 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ofatumumab in Multiple sclerosis relapse: LBCTR2021034775 Clinical Landscape Report 2026
16 October 2026
LBCTR2021034775 clinical landscape for Multiple sclerosis relapse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Daratumumab in Relapse multiple myeloma: NCT06827860 Clinical Landscape Report 2026
16 October 2026
NCT06827860 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.